FIGURE 3.

Changes from baseline (estimated treatment ratios and 95% confidence intervals) in (A) liver enzymes and (B) exploratory biomarkers at weeks 24, 48 and 72 with semaglutide 0.4 mg once daily and placebo. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK‐18, cytokeratin 18 fragments; EOT, end of treatment; FGF‐21, fibroblast growth factor 21; GGT, gamma‐glutamyl transferase, IL‐1RA, interleukin‐1 receptor antagonist; MCP1, monocyte chemoattractant protein‐1; mRNA, messenger RNA; Pro‐C3, released N‐terminal pro‐peptide of type III collagen; Pro‐C6, neo‐epitope in C‐terminal of type VI collagen; SD, standard deviation